HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDV

HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ:INDV - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 83,088 shares of the company's stock, valued at approximately $3,409,000. HighTower Advisors LLC owned about 0.07% of Indivior at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. California State Teachers Retirement System bought a new position in Indivior during the 2nd quarter worth $201,163,000. Fuller & Thaler Asset Management Inc. lifted its position in shares of Indivior by 101.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company's stock worth $228,611,000 after buying an additional 3,201,639 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Indivior in the 4th quarter worth about $82,687,000. State Street Corp increased its position in shares of Indivior by 65.5% during the fourth quarter. State Street Corp now owns 4,659,281 shares of the company's stock valued at $167,175,000 after buying an additional 1,844,532 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Indivior in the 4th quarter worth $61,208,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Price Performance

Shares of INDV opened at $34.49 on Friday. The company's 50-day moving average is $38.18 and its 200-day moving average is $36.03. The firm has a market capitalization of $4.07 billion, a PE ratio of 12.36 and a beta of 0.82. Indivior PLC has a fifty-two week low of $22.22 and a fifty-two week high of $42.81.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The business had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. Analysts predict that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on INDV shares. Weiss Ratings upgraded shares of Indivior from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Friday, September 4th. Barclays dropped their price objective on shares of Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, August 5th. Zacks Research downgraded Indivior from a "strong-buy" rating to a "hold" rating in a report on Monday, June 29th. Finally, Craig Hallum reiterated a "buy" rating and issued a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $45.17.

Insider Buying and Selling

In related news, CAO Woodrow D. Anderson bought 1,500 shares of Indivior stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the acquisition, the chief accounting officer directly owned 27,638 shares of the company's stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christian Heidbreder sold 18,586 shares of the company's stock in a transaction on Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the sale, the insider directly owned 209,337 shares in the company, valued at $8,612,124.18. This trade represents a 8.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company's stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company's key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.